Magnetic Molecular Energizing (MME) has been used effectively for Cardiomyopathy.

MME treatment is considered investigational and is utilized under the direction and auspices of an Investigational Review Board (IRB). The IRB complies with FDA requirements for investigational therapy usage and results review. MME therapy is safe and non-invasive. In some cases, patients may experience some tingling, however, most experience no ill effects and can talk, sleep, read or watch TV.

Facts about Cardiomyopathy
Condition in which the heart muscle is weakened or there is a change in the heart muscle structure preventing effective pumping action.

Types

1. Ischemic – caused by heart attacks and continued coronary artery disease producing lack of blood and oxygen
2. Non-ischemic – caused by alcoholism, chronic drug use, long term severe high blood pressure, viral infections.

Symptoms
Shortness of breath, chest pain, dizziness and fainting, fatigue and swelling of legs associated with minimal to no exertion.

Treatment and Case Results
Medication therapy and often consideration for cardiac transplant surgery. Significant relief of shortness of breath, fatigue, chest pain and ankle swelling as well as improvement in cardiac ejection fraction is noted as the goal of treatment.

A.A. is a 58 year old male with a prior coronary artery obstruction and myocardial infarction (heart attack). He had a history of coronary artery stents placed on 2 occasions. His cardiac ejection fraction was 22% and his complaints included shortness of breath and fatigue. He was unable to walk and required a motorized scooter for activity. He completed 150 hours of MME and stated significant improvement in breathing and energy level. He no longer required a motorized scooter or cane for ambulation.

Although no absolute assurances can be given, there is good reason for optimism for benefit, in individuals who are accepted for treatment, after review and screening. MME appears to enhance and speed the healing of tissues at the cellular and molecular level.